Abstract Mesenchymal stem cells (MSCs) express defined patterns of miRNAs which have been shown to be involved in stemness and differentiation processes. Modulation of miRNA expression by MSCs has been shown to change their biological properties. Moreover, in light of the paracrine hypothesis of MSC action, increasing evidence indicates that miRNA transfer between MSCs and injured cells in tissues accounts for the healing properties exhibited by MSCs. Extracellular vesicles (EVs) are candidates for the trafficking of encapsulated miRNAs between cells, as they are able to cross easily biological barriers and protect nucleic acids from degradation. Moreover, EVs, by expressing the same surface receptors of MSCs, may be recruited to the site of injury as well as the cell of origin. These properties of EVs may be exploited for the generation of specially engineered EVs carrying specific miRNAs for therapeutic purposes.
Introduction
Mesenchymal stem cells (MSCs) are considered to be multipotent progenitor cells, defined according to the International Society for Cellular Therapy, on the basis of their ability to adhere to plastic, to self-replicate, to differentiate into different mesodermal lineages (osteocytes, chondrocytes, and adipocytes), and by their expression of specific surface markers (CD105, CD73 and CD90) [1] . MSCs were initially isolated and characterized from bone marrow, where they play a primary role in supporting haematopoiesis [2, 3] . Subsequently, MSCs were also obtained and expanded from other tissues, including lung [4], adipose tissue [5] , dental pulp [6], placenta [7] , and dermis [8] .
A large body of evidence, present in the literature, indicates that MSC infusion in different animal models of acute injury induces tissue regeneration [9] . For this reason, there is an increasing interest in the application of MSCs in regenerative medicine. Although MSCs exhibit in vitro multilineage differentiation potential and have the capacity to reach injured sites after systemic administration [10] , the in vivo differentiation of MSCs in cells of injured tissues appears to be a rare event. In addition, MSCs are short-lived after in vivo injection, being detectable in various organs and tissues for periods ranging from 24 to 36 h [11, 12] . The current interpretation of these observations is that the biological effects of MSCs mainly depend on paracrine mechanisms that involve the release of bioactive factors. Administration of bioactive soluble factors released by MSCs, in different in vivo models of acute tissue injury, induces inhibition of apoptosis and increases proliferation [13] [14] [15] , leading to tissue regeneration. Moreover, soluble factors are also involved in the immunemodulatory and anti-inflammatory effects of MSCs that contribute to the regeneration of injured tissues [16] . The bioactive factors secreted by MSCs include a variety of growth factors, cytokines and extracellular vesicles (EVs), which are small cellular fragments involved in cell-to-cell communication and capable of altering the behaviour of recipient cells [17] . It has been shown that MSCs release EVs that contribute to tissue repair in different animal models of renal, cardiac and lung injury [18] [19] [20] [21] [22] [23] .
EVs contain proteins and nucleic acids (RNA and small non-coding RNAs) derived from their cell of origin. miRNAs, a group of small non-coding RNAs, have been shown to modulate stemness features and differentiation capacity of MSCs, as well as their biological functions. Moreover, transfer of miRNAs via EVs may modify target cell phenotype and activate regenerative processes.
miRNA Biogenesis and Functions miRNAs were first discovered in nematodes about 20 years ago where they were shown to play a role in determining cell fate. The presence of miRNAs in humans was described about 10 years ago.
Mature miRNAs are produced by multiple steps in the cell. The first miRNA inactive precursor, known as primiRNA, is generated as a stem-loop structure, and is recognized by a complex of different proteins, including DGCR8 and Drosha. These proteins have been shown to process the pri-miRNA into the precursor miRNA (premiRNA), a double-stranded hairpin structure of about 70 nucleotides [24, 25] . The pre-miRNA is then exported from the nucleus to the cytoplasm by another protein complex, Exportin-5 bound to Ran [26] .
The pre-miRNA processing is continued by the RNase III enzyme, Dicer, generating a dsRNA, which lacks the hairpin portion. The resulting two mature single strands (ss) are called guide miRNA and passenger miRNA/ miRNA*. Only one of the ss-miRNAs, which preferentially assemble with the Argonaute proteins in the RNA-induced silencing complex (miRISC), is selected and used to guide sequence-specific silencing of complementary target mRNAs. The miRISC activation induces RNA silencing via endonucleolytic cleavage or translational repression of the target transcript. These two options depend on the specificity of the interaction of the mature miRNA with the 3 0 -UTR of the mRNA [27] . If the miRNA/mRNA interaction is precise, the mRNA is immediately degraded by Ago2, one of the Argonaute family proteins. Otherwise, in the case of no exact interaction, the mRNA is translationally repressed [ [33] .
Different miRNAs have been involved in the ability of MSCs or other stem cells to differentiate into cardiomyocytes [33] . MSCs transfected with miR-133a, which targets EGFR, expressed cardiac-specific markers [34] . Moreover, miR-133a, miR-210, and miR-34a have been associated to the potential of cardiac mesenchymal-like stromal cells to differentiate into cardiomyocytes [35] .
Recently, transplantation of miR-1-transfected MSCs was shown to repair infarct injury and improve heart function by enhancing survival of transplanted cells and cardiomyogenic differentiation [36] . miR-1, miR-133, miR-208, and miR-499 have been described to modulate positively or negatively important cardiac genes [37] . Interestingly, the potential of MSCs and other stem cells to engraft and differentiate into endothelial cells (EC) or vascular smooth muscle cells (VSMC) has also been associated with modulation by miRNAs [33, 38, 39] . miR-1, miR-126, miR-210, miR-145, and miR-143 have been demonstrated to be involved in the differentiation of different stem cells to EC and VSMC [33, 40] .
Bone marrow (BM)-MSCs can differentiate into neuronlike cells under the appropriate culture conditions [41] . miR-9 has been demonstrated to promote MSC neuronal differentiation by enhancing the neural cell-specific marker, microtubule-associated protein 2, via repression of Notch-1 protein [42] .
In neuronal cells differentiated from human MSCs, miR-130 and miR-206 have been described as important regulators of production of neurotransmitter substance P [43] . In addition, miR-34a has been shown to modulate negatively genes implicated in cellular motility and in oxidative phosphorylation in human umbilical cord MSCderived neural precursors [44] . Recently, miR-128, a brain-enriched miRNA, has been found to be necessary for the neural differentiation of BM-MSCs [45] . In particular, Wu et al., demonstrated the ability of miR-128 to attenuate the differentiation of MSCs, through the modulation of Wnt3a, a key component of the Wnt signalling pathway [45] .
MSCs can ameliorate tissue regeneration when injected in different models of liver injury [15] . miRNAs have been involved in the capacity of MSCs to trans-differentiate into hepatocytes [46] . Cui et al. [46] recently found that miR-1246, miR-1290, miR-148a, miR-30a, miR-424, and miR-542-5p were specifically overexpressed during hepatic differentiation of human umbilical cord MSCs. Interestingly, the concomitant overexpression of these miRNAs can convert MSCs more efficiently into mature, functional hepatocytes influencing hepatic gene expression [47 • ].
The relevance of miRNAs in regulating the biological properties of MSCs is emphasized by experiments showing that different factors potentiate or reduce the therapeutic properties of MSCs by means of miRNA modulation. Ng et al. [48] demonstrated a reduction in proliferation and diminished locomotion in MSCs treated with nicotine, in concomitance with an alteration in the miRNA profile; this suggested that miRNAs could play an important role in the effect of nicotine on the regenerative potential of MSCs [48] . Conversely, the preconditioning of MSCs with diazoxide led to improve MSC survival and regenerative activity in myocardial infarction, via induction of miR146a in MSCs [49] . In addition, Nie et al. [50 • ], showed that up-regulation of miR-21, miR-23a, and miR-210 in MSCs submitted to hypoxia enhanced their survival. Moreover, Mao et al. [51] demonstrated the importance of miR-23a in preventing apoptosis of MSCs infused in a rat model of myocardial infarction; they showed that overexpression of miR-23a in transplanted MSCs, after myocardial infarction, improved cardiac function and reduced infarct size. miRNAs may also be involved in the paracrine action of MSCs. In fact, miRNAs derived from MSCs may restore an altered miRNA pattern in injured cells. Indeed, increasing evidence has demonstrated a correlation between altered miRNA patterns and the pathogenesis of different organ injuries [33, 
Extracellular Vesicles as Carriers of Extracellular RNA
EVs may contribute to cell-to-cell communication by membrane expression of specific receptors that can interact with ligands on target cells or, after internalization, EVs may transfer cytoplasmic constituents of the cell of origin, influencing the behaviour of recipient cells [58] . EVs are composed of a heterogeneous population produced by cells via distinct processes. Vesicles may be derived from the endosomal membrane compartments that, after fusion with the plasma membrane, are extruded from the cell surface as exosomes [59] or from budding of the plasma membrane, as shedding vesicles [59] . EVs retain the signature of the cell of origin, and contain cytoplasmic constituents (proteins, nucleic acids and lipids). EVs from MSCs express surface molecules that are characteristic of MSCs (CD29, CD73, CD44, CD105)
[17] and contain cytoplasmic proteins associated with intracellular vesicle biogenesis and trafficking (RAB protein family), along with proteins associated with MSC self-renewal and differentiation (TGF-b, MAPK, PPAR, etc.) [60 • ]. The fact that the same adhesion molecules are expressed by EVs and MSCs may favour the recruitment of EVs to the site of injury, and subsequent delivery of their contents to damaged cells.
Analyses of the nucleic acid content shuttled by MSCderived EVs have demonstrated the presence of nucleic acids, including mRNA, miRNAs, and long noncoding RNAs. The mRNA present in EVs are representative of the multiple differentiation and functional properties of MSCs, including transcripts related to several different cell functions (e.g. the control of transcription, cell proliferation and immune regulation) [17] . EVs from MSCs also contain mRNA for receptors of specific growth factors, such as the insulin-like growth factor 1 (IGF-1) receptor. EVs have been shown to transfer the IGF-1 receptor mRNA to target renal tubular cells in an in vitro model of renal toxic injury induced by cisplatin, inducing proliferation of damaged proximal tubular cells [61] .
EVs derived from human MSCs stimulate in vitro proliferation and apoptosis resistance of renal tubular epithelial cells, and accelerate the functional and morphological recovery in different murine models of kidney injury in vivo [17] [18] [19] [20] . These regenerative effects of EVs have been ascribed to their RNA cargo, as inactivation of RNAs reduced both the in vitro and in vivo effects of EVs [18] [19] [20] . Moreover, it was found that human MSC-derived mRNA were functionally active, as they were translated into proteins in tubular epithelial cells of mice, both in vitro and in vivo [18, 20] .
EVs released by MSCs, also contain specific pre-miRNAs and miRNAs that can be transferred to target cells . Moreover, synthetic miR-133b transfected into MSCs was shown to be transferred to astrocytes and neurons via EVs. In these cells, EV-derived miR-133b was shown to regulate gene expression with a consequent benefit for neurite remodelling and recovery following a stroke [64] . Therapy using engineered-MSCs has also been applied in the functional recovery of the ischemic heart. Kim et al. [65] showed that transgenic induction of miR-210 in MSCs, simulates the pro-survival effects of ischemic preconditioning in the ischemic heart. In this study, the engraftment of engineered-MSC supports the functional recovery, via transfer of miR-210 through gap junction interactions. Recently Yu et al. [66 • ] demonstrated that EVs released by engineered MSCs overexpressing GATA-4 can enhance the cardio-protective effects of MSCs on neonatal rat cardiomyocytes. This protective effect is mediated, in part, by the transfer of anti-apoptotic miRNAs (miR-221/222) contained within EVs; miR-221/222 function by reducing the expression of the pro-apoptotic gene,
Xu et al. [67] demonstrated that the therapeutic infusion of MSCs, in a mouse model of diabetic wound healing, improved recovery by induction of miR-146a. Restoration of miR-146a levels in the lesions, following MSC infusion, reduced pro-inflammatory genes and enhanced wound closure [67] .
Conclusions
In recent years, the possible application of MSC-based therapies has been extensively studied. The role of miRNAs in the context of MSC biology has been shown to be highly relevant, not only in the regulation of the cell fate of MSCs, but also in their biological activity. The mechanism of action of MSCs via release of bio-agents, such as EVs, has opened new therapeutic perspectives. EVs are able to influence the behaviour of target cells by delivering miRNAs, and this effect could, therefore, be exploited in different diseases. Moreover, the use of EVs to replace cells could represent a novel therapeutic strategy, avoiding the possible adverse effects of cell administration. By utilizing the same adhesion receptors of MSCs, EVs may specifically target the site of injury. Moreover, as miRNAs encapsulated within EVs are protected from degrading enzymes and may easily cross biological barriers, EVs can be envisaged as vehicles for the delivery of synthetic miRNAs. Cells can be engineered to produce EVs enriched with specific miRNAs for therapeutic purposes, in pathological conditions where an evident miRNA dysregulation has been observed.
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